| Patient | Judy Garland |
|---|---|
| Date of birth | 1993-06-10 |
| Identifiers | MRN HR-ML005-SYN; SSN (made up) 000-05-6127 |
| Document date | 2026-06-22 |
| Author | Margaret Ellsworth-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth. [S]
Hemoglobin: 12.3 g/dL; MCV: 86 fL; Platelets: 284 10*3/uL; Ferritin: 24 ng/mL; Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.66 mg/dL; eGFR (CKD-EPI 2021): 119 mL/min/1.73 m²; Glucose: 82 mg/dL; AST: 21 U/L; ALT: 18 U/L; GGT: 24 U/L; TSH: 1.9 mIU/L; DAST-10: 6; AUDIT-C: 2; PHQ-9: 14; GAD-7: 13. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-22 | Body height | 151 | cm | S |
| 2026-06-22 | Body weight | 46.5 | kg | S |
| 2026-06-22 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 2026-06-22 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-22 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-06-22 | Heart rate | 98 | /min | S |
| 2026-06-22 | Respiratory rate | 16 | /min | S |
| 2026-06-22 | Body temperature | 36.8 | Cel | S |
| 2026-06-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-22 | Hemoglobin [Mass/volume] in Blood | 12.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-22 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 86 | fL | 80-100 fL | Normal | S |
| 2026-06-22 | Platelets [#/volume] in Blood by Automated count | 284 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-22 | Ferritin [Mass/volume] in Serum or Plasma | 24 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-06-22 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-22 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 119 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-22 | Glucose [Mass/volume] in Serum or Plasma | 82 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 10-35 U/L | Normal | S |
| 2026-06-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 2026-06-22 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 5-40 U/L | Normal | S |
| 2026-06-22 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-06-22 | Total score [DAST-10] | 6 | {score} | S | ||
| 2026-06-22 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-06-22 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 2026-06-22 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 13 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 2026-06-22 to 2026-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 2026-06-22 to 2026-07-20 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-22 to 2026-06-29 | completed | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 2026-06-22 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed | F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed | F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed | G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed | Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |